ReviewCancers2026
Multiple Options, One Objective: Clearer Decisions in Resectable Non-Small Cell Lung Cancer.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly-stage non-small cell lung cancer (NSCLC) accounts for nearly 50% of cases. Surgery remains the cornerstone of curative treatment, but five-year survival is suboptimal, necessitating adjuvant, neoadjuvant, and perioperative strategies including chemotherapy, targeted therapy, and immunotherapy.
methodsWe reviewed randomized trials and conference abstracts from the last decade up to August 2025 on adjuvant, neoadjuvant, and perioperative systemic therapies in resectable NSCLC, focusing on major pathological response, pathological complete response, event-free survival (EFS), and overall survival (OS), and also highlighting several ongoing trials in this setting.
resultsThe review generated a simplified treatment algorithm to assist clinicians in navigating the multiple therapeutic options for resectable NSCLC. Cisplatin-based adjuvant chemotherapy remains standard for stage II-IIIA disease, while targeted therapy (osimertinib, alectinib) improves DFS in EGFR- and ALK-positive tumors. Adjuvant immunotherapy (atezolizumab, pembrolizumab) shows benefit primarily in PD-L1-positive patients, though regulatory approvals differ depending on PD-L1 expression thresholds. Neoadjuvant nivolumab plus chemotherapy significantly improved EFS and OS, particularly in stage IIIA (CheckMate 816). Perioperative regimens with nivolumab, durvalumab, or pembrolizumab show consistent EFS gains, most pronounced in stage III N2 patients. Emerging biomarkers such as residual viable tumor and circulating tumor DNA after surgery may further personalize therapy.
conclusionsTreatment of resectable NSCLC should be individualized based on stage, nodal status, PD-L1 expression, molecular alterations and pCR. Upfront surgery with adjuvant therapy is appropriate for lower-stage disease (IB-IIA), while perioperative chemoimmunotherapy offers maximal benefit in stage II-III, especially N2-positive patients. Biomarker-driven strategies will continue to refine patient selection to stop or continue postoperative treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.